Skip to main content

Table 1 Baseline characteristics of the study population, stratified by disease behavior

From: Computed tomography-based multiple body composition parameters predict outcomes in Crohn’s disease

  All Complicated Inflammatory p value
Demographic data n = 122 n = 54 n = 68  
Age (years) 32.5 ± 12.04 33.85 ± 12.70 30.79 ± 11.41 0.165
Sex     0.181
 Male 95 39 56  
 Female 27 15 12  
Current smoker     0.062
 Yes 15 10 5  
 No 107 44 63  
Locationa     0.263
 L1 49 26 23  
 L2 27 11 16  
 L3 46 17 29  
Perianal disease     0.630
 Yes 32 13 19  
 No 90 41 49  
Duration of disease (years) 2.19 ± 2.93 2.33 ± 2.90 2.08 ± 2.97 0.653
C-reactive protein (mg/L)b 43.03 ± 41.41 (n = 107) 47.02 ± 48.08 (n = 44) 40.25 ± 36.19 (n = 63) 0.408
Serum albumin (g/L)b 35.13 ± 6.67 (n = 120) 34.66 ± 6.78 (n = 54) 35.52 ± 6.57 (n = 66) 0.481
Erythrocyte sedimentation rate (mm/h)b 26.59 ± 22.75 (n = 111) 27.67 ± 23.82 (n = 46) 25.82 ± 22.12 (n = 65) 0.674
BMI (kg/m2) 18.49 ± 2.80 17.88 ± 2.66 19.19 ± 2.82 0.034
Sacorpenia     0.604
 Yes 84 39 45  
 No 38 15 23  
Baseline medications     
Diagnostic anti-tuberculosis therapy 30 8 22 0.025
Nutritional supplement 106 51 55 0.028
Anti-TNF 20 11 9 0.290
Corticosteroids 30 9 21 0.070
Immunomodulator 16 5 11 0.261
Mesalazine 58 20 38 0.038
Follow-up outcomes     
Adverse outcome n = 49 n = 31 n = 18 0.775
Surgery 32 20 12  
Start of anti-TNF therapy 4 2 2  
Escalation of biologic therapy 13 9 4  
  1. Continuous data are expressed as means ± SDs; p values lower than 0.05 are presented in bold
  2. BMI body mass index, TNF tumor necrosis factor
  3. aL1: ileal, L2: colonic, and L3: ileocolonic (Montreal classification)
  4. bPart of patients with missing data on C-reactive protein, serum albumin, and erythrocyte sedimentation rate